Seeking to dramatically bolster its position in the contract development and manufacturing business, Fujifilm is investing $2 billion on a large cell culture production site in the US. The site will feature eight 20,000 liter bioreactors and have the potential for another 24 bioreactors depending on future market demand.

Fujifilm plans to offer drug substance manufacturing and fill and finish services, plus packaging and labeling at the site. Source: Fierce Pharma 6/1/2021